Get the Daily Brief
Latest Biotech News
Parse and Tahoe to build 300M‑cell perturbation atlas to train biology AI
Parse Biosciences and Tahoe Therapeutics announced a collaboration to generate a 300‑million‑cell perturbation single‑cell atlas to train AI models for drug discovery and virtual cell modeling....
Gene-edited cell transplant restores insulin — first patient makes insulin without immunosuppression
Scientists have implanted gene-edited, insulin-producing cells into a man with type 1 diabetes and reported restoration of endogenous insulin production without long-term immunosuppressive...
Arcus shutters TIGIT program after Phase III futility — company refocuses R&D
Arcus Biosciences and partner Gilead halted Phase III work on their anti‑TIGIT antibody domvanalimab after independent data monitoring committees flagged futility in upper gastrointestinal...
FDA eyes boxed warning on COVID vaccines — experts warn of unprecedented move
Reports indicate the U.S. Food and Drug Administration is weighing a boxed (black‑box) warning for COVID‑19 vaccines, a regulatory step that outside experts say would be unprecedented for broadly...
AC Immune posts biomarker wins in Parkinson’s vaccine — regulator talks planned
AC Immune released interim biomarker and safety data from its Phase II Vacsyn program targeting alpha‑synuclein in early Parkinson’s disease and reported signals consistent with potential disease...
Lilly’s triple agonist smashes weight‑loss records — tolerability concerns temper excitement
Eli Lilly’s investigational triple‑agonist retatrutide delivered record weight‑loss results in Phase III testing, with the high‑dose cohort losing an average nearing 29% body weight at 68 weeks,...
Natera expands Signatera trials — buys Foresight to boost MRD sensitivity
Natera announced a collaboration with MEDSIR to run the MiRaDoR trial using Signatera Genome to guide treatment selection in early‑stage hormone receptor‑positive, HER2‑negative breast cancer and...
FDA proposal would loosen rules for companion diagnostics — Class II reclassification eyed
The U.S. Food and Drug Administration proposed reclassifying certain companion diagnostic (CDx) assays from Class III to Class II, which would allow some oncology nucleic‑acid‑based tests to...
Two new oral antibiotics win FDA approval for gonorrhea — expands limited treatment options
Regulators approved two new oral treatments for uncomplicated gonorrhea, adding zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) to the antibiotic armamentarium. Both agents received priority...
House passes INVEST Act — bipartisan bill to ease capital for small biotechs
The U.S. House of Representatives passed the INVEST Act, a BIO‑backed bipartisan bill designed to unlock capital for small, innovative firms by removing regulatory hurdles for companies and...
Disco closes €36M seed to back surfaceome platform — €42M final close fuels target discovery
Disco Pharmaceuticals closed a €36 million seed round (final close) to advance its surfaceome discovery platform toward preclinical development. The funding will support target validation and...
Lilly triple-agonist: 28.7% weight loss, tolerability concerns
Eli Lilly reported jaw-dropping Phase 3 data showing its triple-agonist retatrutide produced mean weight losses approaching 29% in a late-stage study, while trial documents and follow-up reports...
TIGIT programs unravel: Arcus halts late‑stage trials
Arcus Biosciences and partners reported a Phase 3 failure for the anti‑TIGIT antibody domvanalimab when added to PD‑1 blockade and chemotherapy, prompting the company to pause multiple...
AC Immune vaccine: biomarker wins open regulator conversations
Swiss biotech AC Immune released interim Phase II biomarker data from its active immunotherapy Vacsyn (ACI‑7104) that the company says show consistent α‑synuclein, neurofilament light (NfL) and...
ctDNA stakes rise: Exact Sciences and Natera push MRD strategies
Two separate initiatives this week underscored the commercial and clinical push to embed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assays into oncology care. Exact Sciences...
Investors pour cash: China mega‑rounds and European seed fuel discovery startups
Venture financing remained active this week with large rounds and strategic seed closes across geographies. Chinese innovators D3 Bio and Sanegene each secured rounds exceeding $100 million,...
Big‑pharma tie‑ups: Novartis, Relation and Zealand’s $2.5bn metabolic pact
Major industry collaborations continued to shape pipelines: Novartis struck a discovery and development alliance with UK biotech Relation Therapeutics that could deliver up to $1.7 billion in...
FDA vaccine frictions: internal review lands amid public pushback
Regulatory tensions intensified as an FDA staff analysis on pediatric COVID‑19 vaccine safety was circulated internally and triggered media reports that the agency is weighing unprecedented...
CRISPR momentum: in vivo successes and a field‑wide reckoning
CRISPR and gene‑editing took center stage as leaders framed 2025 as a landmark year of in vivo and personalized editing advances. In a wide‑ranging interview, Jennifer Doudna reflected on recent...
Scaling biology: 300M‑cell atlas and AI multi‑omics deals accelerate discovery
Two collaborations signaled rapid scaling of data and AI infrastructure in discovery research. Parse Biosciences and Tahoe Therapeutics agreed to generate a 300 million cell perturbation atlas to...